

Edgar Filing: HYDROMER INC - Form NT 10-Q

HYDROMER INC
Form NT 10-Q
May 16, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12B-25

Commission File Number: 0-10683

NOTIFICATION OF LATE FILING

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q
 Form 10-D Form N-SAR Form N-CSR

For Period Ended: March 31, 2011

Transition Report on Form 10-K
 Transition Report on Form 20-F
 Transition Report on Form 11-K
 Transition Report on Form 10-Q
 Transition Report on Form N-SAR

For the Transition Period Ended:

Read attached instruction sheet before preparing form. Please print or type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify
the Items(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Full Name of Registrant: HYDROMER, INC.
Former Name if Applicable:
Address of principal executive Office (Street and number): 35 Industrial Parkway
City, State and Zip Code: Branchburg, NJ 08876

PART II - RULES 12B-25(b) AND (c)

If the subject report could not be filed without reasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check appropriate box.)

- (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense.
- (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.

PART III - NARRATIVE

Edgar Filing: HYDROMER INC - Form NT 10-Q

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The registrant is unable to file its Form 10-Q for the quarter ended March 31, 2011 by the prescribed date of May 16, 2011 due to not being able reach terms with the mortgage holder on the financial covenants contained in the Company's long term debt instruments. The debt obligations are fully being met (is a performing loan to the mortgage holder), however as a result of the year-to-date results, two covenants are not met. The registrant hopes that it can negotiate a timely agreement so that they can file its Form 10-Q on or prior to the prescribed extended date. Without any agreement, the entire mortgage balance could be "callable" and classified as current.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification Robert Lee (908) 722-5000 (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

A net loss of \$57,868 is being reported for the quarter ended March 31, 2011 (\$0.01 per share) as compared with a net loss of \$206,416 (\$0.04 per share) for the corresponding period the year prior. (See the attached Consolidated Statements of Operations, Consolidated Statements of Cash Flows and Management's Discussions and Analysis.)

Hydromer, Inc

(Name of Registrant as specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 16, 2011

By: /s/ Robert Y. Lee
Robert Y. Lee
Vice President, Chief Financial Officer

HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended March 31,		
	2011 UNAUDITED	2010 UNAUDITED	U
<hr/>			
REVENUES			
Sale of Products	\$ 1,070,400	\$ 845,734	\$ 2,
Service Revenues	274,326	402,766	1,
Royalties and Contract Revenues	206,316	226,668	
	<hr/>	<hr/>	<hr/>
TOTAL REVENUES	1,551,042	1,475,168	4,
	<hr/>	<hr/>	<hr/>
<hr/>			
EXPENSES			
Cost of Sales	483,068	526,601	1,

Edgar Filing: HYDROMER INC - Form NT 10-Q

Operating Expenses	1,101,305	1,316,952	3,
Other Expenses	58,961	56,973	
Gain from Sale of Assets	-	-	
(Benefit) from Income Taxes	(34,424)	(218,942)	(
	<u>1,608,910</u>	<u>1,681,584</u>	<u>4,</u>
TOTAL EXPENSES			

NET LOSS	\$ (57,868)	\$ (206,416)	\$ (

Loss Per Common Share	\$ (0.01)	\$ (0.04)	\$
Weighted Average Number of Common Shares Outstanding	4,772,318	4,772,318	4,

There was no impact to earnings per share from dilutive securities as the resultant would have been anti-dilutive.

HYDROMER, INC. AND CONSOLIDATED SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS

		Nine month March 2011 UNAUDITED

CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss		\$ (510,774) \$
Adjustments to reconcile net loss to net cash used for		

Edgar Filing: HYDROMER INC - Form NT 10-Q

operating activities	
Gain on Sale of Product Lines	-
Depreciation and amortization	303,122
Deferred income taxes	(243,856)
Changes in Assets and Liabilities:	
Trade receivables	210,790
Inventory	(53,416)
Prepaid expenses	600
Other assets	6,400
Accounts payable and accrued liabilities	69,511
Deferred income	94,864
Income taxes payable	-
Net Cash Used in Operating Activities	(122,759)
CASH FLOWS FROM INVESTING ACTIVITIES:	
Cash purchases of property and equipment	(110,254)
Cash payments on patents and trademarks	(140,010)
Redemption of matured short-term investments	440,000
Cash purchases of short-term investments	-
Proceeds Received from the sale of Product Lines	-
Net Cash Provided by Investing Activities	189,736
CASH FLOWS FROM FINANCING ACTIVITIES:	
Repayment of long-term borrowings	(38,526)
Net Cash Used in Financing Activities	(38,526)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:	28,451
Cash and Cash Equivalents at Beginning of Period	843,610
Cash and Cash Equivalents at End of Period	\$ 872,061
Non-Cash Investing and Financing Activities:	
Note Receivable in exchange for Sale of Product Lines	

Edgar Filing: HYDROMER INC - Form NT 10-Q

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

The Company's revenues for the quarter ended March 31, 2011 were \$1,551,042, \$75,874 or 5.1% higher than the \$1,475,168 for the same period the previous year. For the nine month period ended March 31, revenues were \$4,013,059 during the 2011 year, as compared with \$4,600,853 the year before or \$587,794 lower (12.8%). Revenues are comprised of the sale of Products and Services and Royalty and Contract payments.

Product sales were \$1,070,400 for the quarter ended March 31, 2011 as compared to \$845,734 for the same period the year before, a \$224,666 (26.6%) increase: higher due to an increase in Dragonhyde(R) Hoof Bath Concentrate sales of \$232,636, primarily in Europe. The quarter ended March 31, 2010 included \$99,181 in transitional sales from the medical device product lines sold in November 2009. For the nine month period ended March 31, 2011, product sales were \$2,281,134 as compared with \$2,856,840 or \$575,706 (20.2%) lower than the same period the year before. Sales from the divested product lines (including of the product lines sold in April 2009 with its transition period carrying operations into October 2010) accounted for approximately \$798,074 of the difference, offset by \$311,856 in higher Dragonhyde Hoof Bath Concentrates sales. The 2011 results would have been better had it not been for toll manufacturing delays that prevented over \$132,000 of additional sales from occurring in March.

Services revenues, primarily contract coating services, for the three months ended March 31, 2011 was \$274,326 or \$128,440 lower (31.9%) than the \$402,766 the corresponding period the year before, primarily timing differences as overall, Services revenues for the nine months ended March 31, 2011 was \$1,044,715 or \$17,334 lower (1.6%) than the \$1,062,049 the corresponding period the year before.

Royalty and Contract revenues include royalties received and the periodic recurring payments from license, stand still and other agreements other than for product and services. Included in Royalty and Contract revenues are revenues from support and supply agreements. Some of the royalties and support fees are based on the net sales of the final item (to which the Hydromer technology is applied to) and are subject to the reporting of our customers. For the quarter ended March 31, 2011, Royalty and Contract revenues were \$206,316, compared to \$226,668 the same period a year ago. For the nine months ended March 31, 2011, Royalty and Contract revenues were \$687,210, compared with the previous year's \$681,964. We continue entering into new Royalty and Contract revenue agreements, some which begin with our customer's first commercial sale of their product. Once online, including with the commercialization of one of our hydrogel technologies, we anticipate a doubling of this revenue line within the next few years.

When excluding the revenues from the divested product lines, we are reporting a 5.5% gain in total revenues this year's period; a 9.0% gain had they not been any toll manufacturing delays in March 2011. We expect continued revenue growth, particularly in our T-HEXX(R) Animal Health business where a majority of our research and development during the past two years has been focused upon.

Total Expenses for the quarter ended March 31, 2011 were \$1,608,910 as compared with \$1,681,584 the year before, a 4.3% decrease. For the nine months ended March 31, 2011, total expenses were \$4,523,833 as compared with \$5,156,794 the

Edgar Filing: HYDROMER INC - Form NT 10-Q

same period the year before, or an improvement of 12.3%. Reducing expenses for the nine months ended March 31, 2010 was the gain from the sale of product lines of \$335,629. When excluding the gain from sale of product lines, total expenses for the nine months ended March 31, 2010 would have been \$5,492,423 or with the current period \$968,590 (17.6%) better.

For the quarter ended March 31, 2011, the Company's Cost of Goods Sold was \$483,068 as compared with \$526,601 the year prior, lower by \$43,533 or 8.3%. The Cost of Goods Sold attributed to the sold product lines approximated \$5,171 in the March 2011 quarter as compared with approximately \$137,511 in the March 2010 quarter with the cost reduction offset by the higher material Cost of Goods Sold from the increase in [Dragonhyde] product sales revenues. The Cost of Goods Sold for the nine month period was \$1,231,650 or \$762,408 better (38.2%) than the prior year's \$1,994,058, which included approximately \$836,744 relating to the divested product lines.

Operating expenses were \$1,101,305 for the quarter ended March 31, 2011 as compared with \$1,316,952 the year before, lower by \$215,647 or 16.4%. For the nine month period, Operating expenses were \$3,378,516 this year compared with \$3,804,805 the year before, an improvement of \$426,289 (11.2%). Most of the reduction to Operating expenses related to a lower staffing level, including in part due to the divestiture of the medical device product lines, as offset by increases in marketing and sales expenses in our T-HEXX Animal Health business (added tradeshow promotions and related travel and marketing expenditures).

Interest expense, interest income and other income are included in Other Expenses. Interest expense (on the mortgage) for the nine months ended March 31, 2011 and March 31, 2010 were \$149,037 and \$152,823, respectively. Included in Other Income for the 2010 period was the gain from the sale of product lines of \$335,629.

A net loss of \$57,868 (\$0.01 per share) is reported for the quarter ended March 31, 2011 as compared to a net loss of \$206,416 (\$0.04 per share) the year before. For the nine months ended March 31, 2011, a net loss of \$510,774 (\$0.11 per share) is reported compared against a net loss of \$555,941 (\$0.12 per share) for

the same period year before.

Despite sales being \$587,794 lower this year-to-date, of which approximately \$798,074 was attributable to the sale of the medical device product lines, expense reductions, including that beyond relating to the sold product lines, totaled \$632,961. When excluding the \$335,629 gain on the sale of product lines and its related tax expense, total expenses were approximately \$837,695 lower this year. The Company expects to continue improvements to its results coming from increasing revenues with modest increases to its expense base, primarily in expanded sales and marketing costs, including that of new sales representatives.

Financial Condition

Working capital decreased \$61,338 during the three months ended March 31, 2011 and \$753,449 during the nine months then ended.

For the three months ended March 31, 2011, operating activities provided \$366,853 in net cash. For the nine month period ended March 31, 2011 net cash of \$122,759 was used.

Edgar Filing: HYDROMER INC - Form NT 10-Q

The net loss, as adjusted for non-cash expenses of depreciation and amortization and deferred income taxes, used \$451,508 in cash. The net change in other operating assets and liabilities provided \$328,749 in cash, with the primary activities being the collection of trade receivables and customer prepayments and increased accounts payable and accrued expenses as offset by higher inventories, in part due to the toll manufacturer delays.

Investing activities provided \$189,736 and financing activities used \$38,526 during the nine months ended March 31, 2011.

Investing activities for the nine months ended March 31, 2011 included \$110,254 for capital expenditures and \$140,010 towards the Company's patent estate. \$440,000 in short-term investments matured and was converted into cash. Reported under Financing activities was the repayment of the principal portion of the mortgage.

For the quarter ended March 31, 2011, we were near break-even. This is a tremendous turnaround following a \$780,000 annual loss in support fees/cash effective January 1, 2009 and an annualized \$2 million+ loss in revenues (an approximate loss of \$400,000+ in pre-tax profits) related to the medical device product lines sold in 2009. With a continued market penetration from our recently introduced products and the medical coatings introduced years prior, completing their [clinical] evaluations by our customers, we expect a return to profitability soon.